Hypo-active variant of IL-2 and associated decreased T cell activation contribute to impaired apoptosis in autoimmune prone MRL mice

European Journal of Immunology

Volumn 32, Issue 3, 2002, Pages 677-685

  Choi, Youngnim ^a   Simon Stoos, Karen ^b   Puck, Jennifer M ^b  

^a Gangneung Wonju National University   (South Korea)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Autoimmune; IL 2; MRL; T cell

Indexed keywords

CASPASE 3; ENZYME PRECURSOR; FAS ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BCL XL; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENETIC VARIABILITY; HOMEOSTASIS; IMMUNITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE DISEASES; BCL-X PROTEIN; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASES; CONCANAVALIN A; ENZYME INDUCTION; ENZYME PRECURSORS; GENE EXPRESSION REGULATION; GENOTYPE; INTERLEUKIN-2; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED MRL LPR; MICE, INBRED STRAINS; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES;

EID: 0036201483     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200203)32:3<677::AID-IMMU677>3.0.CO;2-I     Document Type: Article

References (44)

1. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
2. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
3. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity
4. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunogenetic analysis
5. Fas/Apo-1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis
6. Novel Fas (CD95/Apo-1) mutations in infants with a lymphoproliferative disorder
7. Spontaneous murine lupus-like syndrome: Clinical and immunopathological manifestations in several strains
8. Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis
9. Abnormalities induced by the mutant gene lpr: Expansion of a unique lymphocyte subset
10. Induction of various autoantibodies by mutant gene lpr in several strains of mice
11. Expression in transgenic mice of dominant interfering fas muatations: A model for human autoimmune lymphoproliferative syndrome
12. Genetic analysis of MRL-lpr mice: Relationship of fas apoptosis gene to disease manifestations and renal disease-modifying loci
13. lpr mice
14. Autocrine feedback death and the regulation of mature T lymphocyte antigen responses
15. The regulation of antigen-induced apoptosis in mature T lymphocytes
16. Mitogen-activated protein kinase kinase antagonized Fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression
17. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis
18. Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis
19. Propriocidal apopotosis of mature T lymphocytes occurs at S phase of the cell cycle
20. + T cells
21. Two CD95 (APO-1/Fas) signaling pathways
22. Existence of at least five interleukin-2 molecules in different mouse strains
23. Glutamine and tetrapeptide repeat variations affect the biological activity of different mouse interleukin-2 alleles
24. QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing IL-2
25. Three-dimensional structure of interleukin-2
26. Alterations in the amino-terminal third of mouse interleukin 2: Effects on biological activity and immunoreactivity
27. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
28. Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma
29. Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L)
30. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria
31. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation
32. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies
33. Interferon-beta mediates stromal cell rescue of T cells from apoptosis
34. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2
35. Delineation of two defects responsible for T cell hyporesponsiveness to concanavalin A in MRL congenic mice
36. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice
37. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells
38. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis
39. Human T cells require IL-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis
40. High expression in bacteria and purification of polymorphic mouse interleukin 2 molecules
41. Defective thymic T cell activation by concanavalin A and anti-CD3 in autoimmune nonobese diabetic mice
42. Role of T cell resistance to activation induced cell death (AICD) in susceptibility to autoimmune diabetes
43. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
44. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta